Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck

Figure 3

Difference of survival comparing altered fractionated radiotherapy with altered fractionated radiotherapy plus chemotherapy using combinations of 5-FU with cisplatin or mitomycin C (Group 1c). This group of trials showed a relevant difference/prolongation in overall treatment time (delta 7 – 28 days) between standard and experimental treatment arm, caused by split course treatment or rapidly alternating radio-chemotherapy. OS = Overall survival; * = 95% confidence limits of 2 year overall survival; delta months = differences of median overall survival; LCL = lower confidence limit of median survival; UCL = upper confidence limit of median survival; N = number of patients.

Back to article page